By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Galapagos NV 

Industriepark Mechelen Noord I, Zone L
Generaal De Wittelaan 11 A
Mechelen    B-2800  Belgium
Phone: 32-15-34-29-00 Fax: 32-15-34-29-01



Company News
Galapagos (GLPG.BR) Reports Additional Data With Filgotinib From The Phase 2 FITZROY Study 4/22/2016 8:35:14 AM
Galapagos (GLPG.BR) And MorphoSys AG Initiate Phase I Study In Joint Antibody Program MOR106 4/7/2016 10:38:37 AM
Galapagos (GLPG.BR) Initiates A Phase IIa Study With GLPG1690 In Idiopathic Pulmonary Fibrosis Patients 4/7/2016 6:41:56 AM
Galapagos (GLPG.BR) Release: Results From 10-Week Analysis Of Phase 2 Study With Filgotinib In Crohn's Disease Presented At ECCO 3/18/2016 9:25:06 AM
ThromboGenics Ltd. (THR.BR) Signs Global And Exclusive In-Licensing Agreement With Galapagos (GLPG.BR) To Develop And Commercialize Integrin Antagonists For The Treatment Of Diabetic Eye Disease 3/17/2016 12:57:01 PM
Galapagos (GLPG.BR) Doses First CF Patient With G551D Mutation In SAPHIRA 1 Study 3/17/2016 8:26:15 AM
Galapagos (GLPG.BR) Selected For BEL 20 Index 3/7/2016 9:31:49 AM
Galapagos (GLPG.BR) Reports Largest Cash Balance Ever 3/3/2016 2:35:23 PM
Galapagos (GLPG.BR) Receives Transparency Notification From Johnson & Johnson (JNJ) 3/2/2016 7:49:55 AM
Galapagos (GLPG.BR) Starts SAPHIRA Phase II Study With GLPG1837 In Cystic Fibrosis Patients 2/17/2016 7:37:39 AM